A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Formulation and Determination of Intravenous Pharmacokinetics

Trial Profile

A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Formulation and Determination of Intravenous Pharmacokinetics

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs MEDI-7219 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 22 Jan 2018 Planned End Date changed from 16 Jul 2018 to 17 Aug 2018.
    • 22 Jan 2018 Planned primary completion date changed from 16 Jul 2018 to 17 Aug 2018.
    • 18 Dec 2017 Planned End Date changed from 20 Jul 2018 to 16 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top